CytoDyn secures $16.5 million in financing for leronlimab development
VANCOUVER, Washington, Sept. 01, 2026 /CourierPR/ -- CytoDyn Inc., a clinical-stage oncology company developing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, has secured $16.5 million in financing. The company announced the deal, facilitated by Paulson Investment Company as placement agent, signaling strong investor confidence in the drug’s potential across multiple indications, including triple-negative breast cancer and metastatic colorectal cancer.
According to Robert E. Hoffman, Chief Financial Officer of CytoDyn, the successful execution of this financing underscores continued support for the company's clinical strategy and the long-term potential of leronlimab. Hoffman noted, “We are encouraged by the continued commitment of our existing investors, as well as the strong engagement from new investors, which we believe underscores growing interest in leronlimab’s potential in immuno-oncology.”
Hoffman added, “With this financing expected to fund operations into the second half of 2027, we are well positioned to focus on clinical execution and the pursuit of strategic priorities that we believe will create meaningful long-term value for our shareholders.”
The net proceeds from the financing will primarily be used to advance CytoDyn’s clinical development programs, including ongoing and planned clinical trials, regulatory activities, and data analysis. The company may also allocate a portion of the funds to support manufacturing readiness, regulatory and compliance infrastructure, and general working capital.
Leronlimab’s development is centered on its ability to modulate the immune system and has shown promise in treating various cancers and infectious diseases. The company's ongoing and planned clinical trials aim to further evaluate the drug's efficacy and safety in treating patients with these conditions.
For more detailed information on the company's historical financing activities and key terms of related agreements, interested parties can refer to CytoDyn’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K filed on August 31, 2026.
CytoDyn remains committed to advancing therapeutic innovation and improving patients' quality of life. The company’s mission, guided by integrity, responsibility, and service, aims to bring transformative treatments to patients worldwide.
The company’s focus on leronlimab’s potential in immuno-oncology reflects a growing interest in the drug’s multifaceted therapeutic applications. With the new funding, CytoDyn is poised to continue its clinical development efforts and drive forward in the pursuit of meaningful long-term value for its shareholders.